Page 108 - 2018_12-Haematologica-web

I.S. Pagani et al.
Distribution of genomic breakpoints in
chronic myeloid leukemia: analysis of 308
patients. Leukemia. 2013;27(10):2105-2107.
6. Alikian M, Ellery P, Forbes M, et al. Next- Generation Sequencing-Assisted DNA- Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia Patients. J Mol
Diagn. 2016;18(2):176-189.
7. Linhartova J, Hovorkova L, Soverini S, et al.
Characterization of 46 patient-specific BCR- ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next gen- eration sequencing. Mol Cancer. 2015; 14:89.
8. Ross DM, Branford S, Moore S, Hughes TP. Limited clinical value of regular bone mar- row cytogenetic analysis in imatinib-treat- ed chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Leukemia. 2006;20(4):664-670.
9. Yeung DT, Osborn MP, White DL, et al. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood. 2015;125(6):915-923.
10. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872- 884.
11. Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone mar- row cytogenetics. Br J Haematol. 1999; 107(3):587-599.
12. Score J, Calasanz MJ, Ottman O, et al. Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mech- anisms of formation. Leukemia. 2010;
24(10):1742-1750.
13. Ross DM, Branford S, Seymour JF, et al.
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia. 2010;24(10):1719- 1724.
14. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1(8476):307-310.
15. Hanfstein B, Muller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for long-term pro- gression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012;26(9):2096-2102.
16. Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts out- comes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014;123(9):1353-1360.
17. Marum JE, Branford S. Current develop- ments in molecular monitoring in chronic myeloid leukemia. Ther Adv Hematol. 2016;7(5):237-251.
18. Hughes TP, Ross DM. Moving treatment- free remission into mainstream clinical practice in CML. Blood. 2016;128(1):17-23.
19. Mahon FX, Etienne G. Deep molecular response in chronic myeloid leukemia: the new goal of therapy? Clin Cancer Res. 2014;20(2):310-322.
20. Saussele S, Richter J, Hochhaus A, Mahon FX. The concept of treatment-free remis- sion in chronic myeloid leukemia. Leukemia. 2016;30(8):1638-1647.
21. Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. Nature. 2005;435(7046):1267-1270.
22. Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M. Dynamic model- ing of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med. 2006;12(10):1181- 1184.
23. Jain P, Kantarjian H, Patel KP, et al. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 2016;127(10):1269-1275.
24. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003; 17(12):2318-2357.
25. Branford S, Hughes TP, Rudzki Z. Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymor- phism within the BCR gene. Br J Haematol. 2002;117(4):875-877.
26. Kumari A, Brendel C, Hochhaus A, Neubauer A, Burchert A. Low BCR-ABL expression levels in hematopoietic precur- sor cells enable persistence of chronic myeloid leukemia under imatinib. Blood. 2012;119(2):530-539.
27. Mori S, Vagge E, le Coutre P, et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol. 2015;90(10):910-914.
28. Ross DM, Masszi T, Gomez Casares MT, et al. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. J Cancer Res Clin Oncol. 2018; 144(5):945-954.
2032
haematologica | 2018; 103(12)